Has Jonathan Benitez-Gonzalez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,569 in general payments to Jonathan Benitez-Gonzalez, MD across 204 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Benitez-Gonzalez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Benitez-Gonzalez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Benitez-Gonzalez, MD

Interventional Cardiology · Rio Grande, PRNPI 1265861769

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.7%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 59.6% of the total. Reporting peaked in 2023 at $7,909 and has fallen 88.4% since, to $921 in 2025.

$18,569in general payments, 2019–2025

Across 204 payments — averaging $91.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$11K
Boston Scientific$2K
Abbott$1K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$672
AstraZeneca$470
Cook Medical LLC$450
plus $3K from 21 others

What the payments were for

Grants$6,66536%
Travel & lodging$1,1626%
Food & beverage$10,52157%
Education$2211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	65	$11,063
Boston Scientific	25	$2,118
Abbott	11	$1,260
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	26	$672
AstraZeneca	11	$470
Cook Medical LLC	2	$450
Inari Medical, Inc.	3	$384
Philips North America LLC	4	$351
Amgen	12	$246
Johnson & Johnson	8	$203
Pfizer	4	$160
Cardiovascular Systems Inc.	1	$148
Novartis	6	$131
Boehringer Ingelheim	1	$125
Pfizer Pharmaceuticals LLC	1	$121
Chiesi USA, Inc.	3	$109
PBG Puerto Rico LLC	6	$105
E.r. Squibb & Sons, L.L.C.	5	$95
Merck	1	$92
Penumbra, Inc.	1	$63
Cathworks, Inc.	1	$45
Cordis US CORP.	1	$35
Akcea Therapeutics, Inc.	2	$33
Cvrx, Inc.	1	$27
Abiomed	1	$26
United Therapeutics Corporation	1	$21
CSL Behring	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,569 in reported general payments places this provider in the 60th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$767

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	22	$173

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Rio Grande

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →